ZA989876B - Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor. - Google Patents

Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor.

Info

Publication number
ZA989876B
ZA989876B ZA9809876A ZA989876A ZA989876B ZA 989876 B ZA989876 B ZA 989876B ZA 9809876 A ZA9809876 A ZA 9809876A ZA 989876 A ZA989876 A ZA 989876A ZA 989876 B ZA989876 B ZA 989876B
Authority
ZA
South Africa
Prior art keywords
ateriosus
cyclooxygenase
inhibitors
prevention
maintaining
Prior art date
Application number
ZA9809876A
Other languages
English (en)
Inventor
Philip Needleman
Jaime Masferrer
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of ZA989876B publication Critical patent/ZA989876B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9809876A 1997-10-31 1998-10-29 Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor. ZA989876B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6388997P 1997-10-31 1997-10-31

Publications (1)

Publication Number Publication Date
ZA989876B true ZA989876B (en) 1999-10-29

Family

ID=22052179

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9809876A ZA989876B (en) 1997-10-31 1998-10-29 Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor.

Country Status (9)

Country Link
EP (1) EP1027048A2 (https=)
JP (1) JP2001521889A (https=)
AR (1) AR014000A1 (https=)
AU (1) AU758566B2 (https=)
BR (1) BR9813164A (https=)
CA (1) CA2308639A1 (https=)
TW (2) TW200404535A (https=)
WO (1) WO1999022720A2 (https=)
ZA (1) ZA989876B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001274858A1 (en) * 2000-06-08 2001-12-17 Board Of Regents, The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
EP1745791B1 (en) 2003-05-07 2013-06-26 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6718494A (en) * 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
WO1997031631A1 (en) * 1996-02-27 1997-09-04 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents

Also Published As

Publication number Publication date
EP1027048A2 (en) 2000-08-16
WO1999022720A3 (en) 1999-08-26
JP2001521889A (ja) 2001-11-13
AU1192699A (en) 1999-05-24
TW577739B (en) 2004-03-01
AR014000A1 (es) 2001-01-31
TW200404535A (en) 2004-04-01
BR9813164A (pt) 2000-08-22
WO1999022720A2 (en) 1999-05-14
AU758566B2 (en) 2003-03-27
CA2308639A1 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
IL125416A0 (en) Methods and apparatus for connecting openings formed in adjacent blood vessels or other anatomical structures
AU4897797A (en) Device for the treatment of patent ductus arteriosus and method of using the device
IL142992A0 (en) Cardiac assist system and method thereof
ZA983249B (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
HUP0102208A3 (en) Water treatment product and method
EP1014873A4 (en) CYROSURGICAL SYSTEM AND METHOD
AU3142897A (en) Heart preservation and transportation apparatus and method
HUP0201482A3 (en) Method and apparatus for the manufacture of meat
ZA97947B (en) Method and apparatus for applying tissue seaplant.
PL327827A1 (en) Method of retarding the skin photoageing process
EP1022985A4 (en) LYSIS APPARATUS AND METHOD
GB0013520D0 (en) System and method for enabling the provision of goods or services
NO972426D0 (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
EP0592997A3 (en) Method and device for measuring the thickness of a tissue section.
ZA989876B (en) Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor.
GB9403444D0 (en) Golden cream shrimp and method for the same
NO971083L (no) Fremgangsmåte for restfri oppdeling av en kvadratformet blokk av dypfryst næringsmiddel i små kvadratformede porsjoner, særlig små pinner, og saglinje for gjennomföring av fremgangsmåten
TW373643U (en) Method and apparatus for the treatment of stainless steel surfaces
AU6502194A (en) Oestriol-containing hormonal agent for the prophylaxis and treatment of arterial conditions in humans, method of preparing it and its use
AU7660494A (en) Method and device for the study, diagnosis and treatment of the cardiovascular system, and in particular the arterial system
IL131802A0 (en) Method and system for treatment of food items
SI0971714T1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
GB9716490D0 (en) Method and apparatus for performing transactions
GB9918193D0 (en) Isolation method and apparatus
AU6404698A (en) Treatment methods for obtaining therapeutic products and resulting products